Nienke J Vet1,2, Janneke M Brussee3, Matthijs de Hoog1,2, Miriam G Mooij1,4, Carin W M Verlaat5, Isabel S Jerchel6, Ron H N van Schaik7, Birgit C P Koch8, Dick Tibboel1,4, Catherijne A J Knibbe3,9, Saskia N de Wildt1,4. 1. 1 Intensive Care. 2. 2 Department of Pediatrics. 3. 3 Division of Pharmacology, Leiden Academic Center for Drug Research, Leiden University, Leiden, the Netherlands. 4. 4 Department of Pediatric Surgery, and. 5. 5 Intensive Care, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands. 6. 6 Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands. 7. 7 Department of Clinical Chemistry and. 8. 8 Department of Hospital Pharmacy, Erasmus MC, Rotterdam, the Netherlands; and. 9. 9 Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein, the Netherlands.
Abstract
RATIONALE: Various in vitro, animal, and limited human adult studies suggest a profound inhibitory effect of inflammation and disease on cytochrome P-450 3A (CYP3A)-mediated drug metabolism. Studies showing this relationship in critically ill patients are lacking, whereas clearance of many CYP3A drug substrates may be decreased, potentially leading to toxicity. OBJECTIVES: To prospectively study the relationship between inflammation, organ failure, and midazolam clearance as a validated marker of CYP3A-mediated drug metabolism in critically ill children. METHODS: From 83 critically ill children (median age, 5.1 mo [range, 0.02-202 mo]), midazolam plasma (n = 532), cytokine (e.g., IL-6, tumor necrosis factor-α), and C-reactive protein (CRP) levels; organ dysfunction scores (Pediatric Risk of Mortality II, Pediatric Index of Mortality 2, Pediatric Logistic Organ Dysfunction); and number of failing organs were prospectively collected. A population pharmacokinetic model to study the impact of inflammation and organ failure on midazolam pharmacokinetics was developed using NONMEM 7.3. MEASUREMENTS AND MAIN RESULTS: In a two-compartmental pharmacokinetic model, body weight was the most significant covariate for clearance and volume of distribution. CRP and organ failure were significantly associated with clearance (P < 0.01), explaining both interindividual and interoccasional variability. In simulations, a CRP of 300 mg/L was associated with a 65% lower clearance compared with 10 mg/L, and three failing organs were associated with a 35% lower clearance compared with one failing organ. CONCLUSIONS: Inflammation and organ failure strongly reduce midazolam clearance, a surrogate marker of CYP3A-mediated drug metabolism, in critically ill children. Hence, critically ill patients receivingCYP3A substrate drugs may be at risk of increased drug levels and associated toxicity.
RCT Entities:
RATIONALE: Various in vitro, animal, and limited human adult studies suggest a profound inhibitory effect of inflammation and disease on cytochrome P-450 3A (CYP3A)-mediated drug metabolism. Studies showing this relationship in critically ill patients are lacking, whereas clearance of many CYP3A drug substrates may be decreased, potentially leading to toxicity. OBJECTIVES: To prospectively study the relationship between inflammation, organ failure, and midazolam clearance as a validated marker of CYP3A-mediated drug metabolism in critically ill children. METHODS: From 83 critically ill children (median age, 5.1 mo [range, 0.02-202 mo]), midazolam plasma (n = 532), cytokine (e.g., IL-6, tumor necrosis factor-α), and C-reactive protein (CRP) levels; organ dysfunction scores (Pediatric Risk of Mortality II, Pediatric Index of Mortality 2, Pediatric Logistic Organ Dysfunction); and number of failing organs were prospectively collected. A population pharmacokinetic model to study the impact of inflammation and organ failure on midazolam pharmacokinetics was developed using NONMEM 7.3. MEASUREMENTS AND MAIN RESULTS: In a two-compartmental pharmacokinetic model, body weight was the most significant covariate for clearance and volume of distribution. CRP and organ failure were significantly associated with clearance (P < 0.01), explaining both interindividual and interoccasional variability. In simulations, a CRP of 300 mg/L was associated with a 65% lower clearance compared with 10 mg/L, and three failing organs were associated with a 35% lower clearance compared with one failing organ. CONCLUSIONS:Inflammation and organ failure strongly reduce midazolam clearance, a surrogate marker of CYP3A-mediated drug metabolism, in critically ill children. Hence, critically ill patients receiving CYP3A substrate drugs may be at risk of increased drug levels and associated toxicity.
Authors: Niina Kleiber; Ron A A Mathôt; Maurice J Ahsman; Enno D Wildschut; Dick Tibboel; Saskia N de Wildt Journal: Br J Clin Pharmacol Date: 2017-02-27 Impact factor: 4.335
Authors: Anne van Rongen; Margreke J E Brill; Janelle D Vaughns; Pyry A J Välitalo; Eric P A van Dongen; Bert van Ramshorst; Jeffrey S Barrett; Johannes N van den Anker; Catherijne A J Knibbe Journal: Clin Pharmacokinet Date: 2018-05 Impact factor: 6.447
Authors: Linda G Franken; Anniek D Masman; Brenda C M de Winter; Frans P M Baar; Dick Tibboel; Teun van Gelder; Birgit C P Koch; Ron A A Mathot Journal: Br J Clin Pharmacol Date: 2017-03-31 Impact factor: 4.335
Authors: Mary K Dahmer; Guangyu Yang; Min Zhang; Michael W Quasney; Anil Sapru; Heidi M Weeks; Pratik Sinha; Martha A Q Curley; Kevin L Delucchi; Carolyn S Calfee; Heidi Flori Journal: Lancet Respir Med Date: 2021-12-06 Impact factor: 30.700
Authors: Sebastiaan C Goulooze; Erwin Ista; Monique van Dijk; Dick Tibboel; Elke H J Krekels; Catherijne A J Knibbe Journal: AAPS J Date: 2021-05-17 Impact factor: 4.009